Published • loading... • Updated
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Summary by Star Local
15 Articles
15 Articles
Star Local+11 Reposted by 11 other sources
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance - PressReach
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% IRVING, Texas, Nov. 4, 2026 /PRNewswire/ — Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio … Continue reading "Caris Life Sciences Reports Third Quarter 2026 Financial R…
Coverage Details
Total News Sources15
Leaning Left1Leaning Right1Center8Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
Factuality
To view factuality data please Upgrade to Premium
